Trial · NCT03863080
Results by group131
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 131
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind Treatment Period: Placebo | Any AE | 5 | Participants | |
| Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind Treatment Period: RVT-1401 340 mg/Week | Any AE | 4 | Participants | |
| Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind Treatment Period: RVT-1401 680 mg/Week | Any AE | 5 | Participants | |
| Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind Treatment Period: Placebo | Any SAE | 0 | Participants | |
| Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind Treatment Period: RVT-1401 340 mg/Week | Any SAE | 0 | Participants | |
| Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind Treatment Period: RVT-1401 680 mg/Week | Any SAE | 1 | Participants | |
| Open-Label Extension Period: Number of Participants Reporting AEs and SAEs | Open-Label Extension Period: RVT-1401 340 mg Biweekly | Any AE | 10 | Participants | |
| Open-Label Extension Period: Number of Participants Reporting AEs and SAEs | Open-Label Extension Period: RVT-1401 340 mg Biweekly | Any SAE | 1 | Participants | |
| Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs | Double-blind Treatment Period: Placebo | 0 | Participants | ||
| Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs | Double-blind Treatment Period: RVT-1401 340 mg/Week | 0 | Participants | ||
| Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs | Double-blind Treatment Period: RVT-1401 680 mg/Week | 0 | Participants | ||
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs | Double-blind Treatment Period: Placebo | 0 | Participants | ||
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs | Double-blind Treatment Period: RVT-1401 340 mg/Week | 0 | Participants | ||
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs | Double-blind Treatment Period: RVT-1401 680 mg/Week | 0 | Participants | ||
| Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | Double-blind Treatment Period: Placebo | 0 | Participants | ||
| Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | Double-blind Treatment Period: RVT-1401 340 mg/Week | 0 | Participants | ||
| Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | Double-blind Treatment Period: RVT-1401 680 mg/Week | 0 | Participants | ||
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | Double-blind Treatment Period: Placebo | 0 | Participants | ||
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | Double-blind Treatment Period: RVT-1401 340 mg/Week | 0 | Participants | ||
| Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters | Double-blind Treatment Period: RVT-1401 680 mg/Week | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03863080/results